Get the Stockscreener App
294.25
1.08%
-3.525
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $294.25, with a volume of 847.06K.
It is down -1.08% in the last 24 hours and up +12.41% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$297.78
Open:
$299.16
24h Volume:
847.06K
Relative Volume:
0.25
Market Cap:
$159.74B
Revenue:
$33.42B
Net Income/Loss:
$4.09B
P/E Ratio:
38.97
EPS:
7.55
Net Cash Flow:
$11.49B
1W Performance:
+3.21%
1M Performance:
+12.41%
6M Performance:
-5.74%
1Y Performance:
-0.44%
1-Day Range:
$293.76
$299.61
1-Week Range:
$283.40
$309.49
52-Week Range:
$253.30
$346.85
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
294.29 | 159.74B | 33.42B | 4.09B | 11.49B | 7.55 |
|
LLY
Lilly Eli Co
|
880.87 | 827.20B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
86.39 | 386.95B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
153.73 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
|
ABBV
Abbvie Inc
|
192.06 | 341.01B | 56.33B | 4.28B | 15.62B | 2.40 |
|
MRK
Merck Co Inc
|
87.88 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen Inc. (NASDAQ:AMGN) Shares Bought by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Ledyard National Bank Has $7.52 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
What is William Blair's Estimate for Amgen FY2025 Earnings? - MarketBeat
Consolidated Portfolio Review Corp Invests $1.22 Million in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
FY2026 Earnings Estimate for Amgen Issued By Leerink Partnrs - MarketBeat
Encompass Wealth Advisors LLC Has $1.57 Million Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Financial Advocates Investment Management Has $2.64 Million Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Antidote Market: To Witness Massive Growth by 2032 | Amgen, BMS, Mylan - openPR
Amgen: Multiple Strengths, But The Valuation Is A Concern (AMGN) - Seeking Alpha
Amgen SVP Nancy Grygiel sells stock for $483,807 - MSN
Amgen Inc. (NASDAQ:AMGN) Q4 2024 Earnings Call Transcript - MSN
Amgen Stock Has Surged. Here’s Where It’s Headed Next. - Barron's
Amgen: The Charts Didn't Lie, Upgrade To Buy (NASDAQ:AMGN) - Seeking Alpha
Amgen 4Q Results - Contract Pharma
Daiwa Securities Adjusts Amgen's Price Target to $350 From $360 -February 06, 2025 at 12:00 pm EST - Marketscreener.com
Cell Therapy Market Deep Research Report with Forecast by 2032 | Amgen Inc., Johnson & Johnson Services Inc., - EIN News
Uber To $80? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Q1 Earnings Forecast for Amgen Issued By Leerink Partnrs - MarketBeat
YANKCOM Partnership Invests $341,000 in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen (NASDAQ:AMGN) Has Announced That It Will Be Increasing Its Dividend To $2.38 - Yahoo Finance
Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade) - Seeking Alpha
Bleakley Financial Group LLC Trims Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Vision Capital Management Inc. Sells 5,942 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Trilogy Capital Inc. Purchases 886 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
A $1bn Biosimilar? Amgen Enjoying Early Monopoly On Aflibercept Competition - Citeline News & Insights
Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Absher Wealth Management LLC - MarketBeat
Choreo LLC Raises Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Stratos Wealth Advisors LLC - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Stratos Wealth Partners LTD. - MarketBeat
Retirement Systems of Alabama Sells 851 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Dow up 264 points on gains for Amgen, NVIDIA Corp. shares - MSN
Amgen Inc. Reports Robust 2024 Growth Amid Challenges - TipRanks
Valley National Advisers Inc. Decreases Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by CENTRAL TRUST Co - MarketBeat
Golden State Equity Partners Has $1.34 Million Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Sylvest Advisors LLC Purchases Shares of 2,853 Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen (NASDAQ:AMGN) Posts Earnings Results, Beats Expectations By $0.27 EPS - MarketBeat
Danaher Unit Fights Amgen Subpoena in Fresenius Biosimilars Case - Bloomberg Law
Amgen, NVIDIA Corp. share gains contribute to Dow's nearly 150-point climb - MSN
Amgen (NASDAQ:AMGN) Issues Earnings Results, Beats Estimates By $0.27 EPS - MarketBeat
Erste Group lifts Amgen stock rating to Buy on strong margins - MSN
Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating - Seeking Alpha
Why Amgen (AMGN) Stock Is Trading Up Today - MSN
Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead - Benzinga
Amgen obesity drug on hold; Regeneron sets first dividend - BioPharma Dive
Amgen beats estimates as shares jump upwards - The Pharma Letter
AMGN's Q4 Earnings Beat, Obesity Candidate Under FDA Clinical Hold - Yahoo Finance
Amgen Options Trading: A Deep Dive into Market Sentiment - Benzinga
Earnings Miss? Amgen’s Dividend Still a Bright Spot - Inkl
Amgen Shrugs Off A Surprise Setback For One Of Its Obesity Drugs - Yahoo! Voices
TD Cowen Adjusts Amgen's Price Target to $389 From $383 -February 05, 2025 at 09:37 am EST - Marketscreener.com
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):